Home › Major Depressive Disorder › Georgia
Major Depressive Disorder clinical trials in Georgia
33 studies for Major Depressive Disorder are looking for participants at sites in Georgia.
Cities in Georgia
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- CenExel iResearch, LLC, Decatur
- AGILE Clinical Research Trials, LLC, Sandy Springs
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 1, 2026 · NCT07775300A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Agile Clinical Research Trials, LLC, Atlanta
- Accelerated Clinical Research Group LLC, Snellville
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Oct 1, 2026 · NCT07573176Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
- Emory Healthcare, Atlanta
Recruiting
Ages 22 to 85 · All sexes · Updated Sep 29, 2026 · NCT07594483JAK Signaling in Depression
- Emory University, Atlanta
RecruitingPhase 2
Ages 25 to 55 · All sexes · Updated Sep 28, 2026 · NCT07003997Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Advanced Discovery Research, Atlanta
- Agile Clinical Research Trials, LLC, Atlanta
- iResearch Atlanta LLC, Decatur
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 25, 2026 · NCT06559306A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Evergreen Clinical Trials, Norcross
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07621237Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- The Emory Clinic, Atlanta
- CenExeli Research LLC, Decatur
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT05850689A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Peachford Hospital-Atlanta Behavioral Research, Atlanta
RecruitingPhase 3
Ages 12 to 17 · All sexes · Updated Sep 25, 2026 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Psych Atlanta, Marietta
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06793397Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Snellville
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 24, 2026 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Augusta
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07105111A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Atlanta
- Seaport Investigator Site, Decatur
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Sep 14, 2026 · NCT07065240Leucine in Midlife Depression
- Emory University Hospital, Atlanta
RecruitingPhase 2
Ages 35 to 65 · All sexes · Updated Sep 11, 2026 · NCT06580145A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Delricht Research, Atlanta
- Emory University Brain Health Center, Atlanta
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 8, 2026 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Decatur
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 2, 2026 · NCT07610473Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- Emory University Hospital, Atlanta
Recruiting
Ages 22 to 70 · All sexes · Updated Aug 28, 2026 · NCT06423430A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, Atlanta
- Draig Clinical Site, Decatur
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 26, 2026 · NCT07300969NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06911112A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- CenExel - Atlanta Center for Medical Research, Atlanta
- CenExel - iResearch Atlanta, Decatur
- CenExel - iResearch Savannah, Savannah
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Aug 10, 2026 · NCT07592689A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- CenExel iResearch, LLC, Decatur
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 6, 2026 · NCT07412756A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Advanced Discovery Research, Atlanta
- Synexus - Atlanta, Atlanta
- Psych Atlanta, Pc, Marietta
- and 1 more
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Aug 3, 2026 · NCT06775379Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- CenExel iRS (iResearch Savannah), Savannah
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Aug 3, 2026 · NCT06547489A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Denali Health Atlanta, LLC, Stone Mountain
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Jul 27, 2026 · NCT07115329Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT06966401Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Atlanta
- Clinical Research Site, Norcross
- Clinical Research Site, Snellville
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 24, 2026 · NCT07484217A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Trialmed /ID# 277601, Atlanta
- Evergreen Clinical Trials - Norcross /ID# 279421, Norcross
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jun 15, 2026 · NCT07276997Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
- Emory University, Atlanta
RecruitingEarly phase 1Healthy volunteers welcome
Ages 18 to 65 · All sexes · Updated May 26, 2026 · NCT05327699A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- CenExcel, Decatur
- CenExel, Savannah
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated May 11, 2026 · NCT06524830REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
- Savannah VA Clinic, Savannah
RecruitingPhase 3Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Apr 29, 2026 · NCT07280065Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Georgia, Athens
RecruitingObservational study
Ages 18 to 40 · All sexes · Updated Mar 10, 2026 · NCT06740383Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #112, Decatur
- Autobahn Site #142, Peachtree Corners
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jan 20, 2026 · NCT06633016Study of ALTO-300 in MDD
- Site 224, Savannah
- Site 208, Snellville
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jul 24, 2025 · NCT05922878A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Atlanta
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated Jan 23, 2025 · NCT06223880From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.